CoChat

Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer

Open access

Published version of a preprint

The DOI matches its Crossref record; 87 of the 87 references it cites were found in a registry or an index.

Abstract

Dysregulation of the PI3K-AKT-mTOR signaling network is a prominent feature of breast cancers. However, clinical responses to drugs targeting this pathway have been modest, possibly because of dynamic changes in cellular signaling that drive resistance and limit drug efficacy. Using a quantitative chemoproteomics approach, we mapped kinome dynamics in response to inhibitors of this pathway and identified signaling changes that correlate with drug sensitivity. Maintenance of AURKA after drug treatment was associated with resistance in breast cancer models. Incomplete inhibition of AURKA was a common source of therapy failure, and combinations of PI3K, AKT or mTOR inhibitors with the AURKA inhibitor MLN8237 were highly synergistic and durably suppressed mTOR signaling, resulting in apoptosis and tumor regression in vivo. This signaling map identifies survival factors whose presence limits the efficacy of targeted therapies and reveals new drug combinations that may unlock the full potential of PI3K-AKT-mTOR pathway inhibitors in breast cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41589-018-0081-9

Cites

87 of 87 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 87 references

Cited by

See all 95

Metadata

Authors
Donnella, H. J., Webber, J. T., Levin, R. S., Camarda, R., Momcilovic, O., Bayani, N., Shah, K. N., Korkola, J. E., Shokat, K. M., Goga, A., Gordan, J. D., & Bandyopadhyay, S.
Affiliations
  • University of California, San Francisco (US)
  • Oregon Health & Science University (US)
  • Howard Hughes Medical Institute (US)
Corresponding author
  • Gordan, John D.
  • Bandyopadhyay, Sourav
Venue
Nature Chemical Biology
Published
2018-06-25
Volume
14
Issue
8
Pages
768-777
ISSN
  • 1552-4450 (ISSN-L)
  • 1552-4469
OpenAlex
W2811244167
Cited by
90
References
87
Citations by year
2026: 7 · 2025: 9 · 2024: 11 · 2023: 21 · 2022: 7 · 2021: 12 · 2020: 13 · 2019: 6 · 2018: 4
FWCI
3.20
Type
journal article
Language
en
Open access
Licence
  • cc-by
  • www.springer.com/tdm (tdm)
Locations
  • Nature Chemical Biology (publishedVersion)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • Oregon Health and Science University
  • National Cancer Institute (R01CA170447, U01CA217882, U01CA168370, T32CA108462)
  • National Institute of General Medical Sciences (T32GM067547, T32GM008568, T32GM007175, R01GM107671)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
Keywords
breast cancer, PI3K/AKT/mTOR pathway, AURKA, drug resistance, PI3K inhibitors, AKT inhibitors, mTOR inhibitors, MLN8237, chemoproteomics, drug synergy, targeted therapy, apoptosis, tumor regression
MeSH terms
Phosphoinositide-3 Kinase Inhibitors, Antineoplastic Agents, Azepines, Breast Neoplasms, Drug Screening Assays, Antitumor, Female, Humans, Plant Proteins, Pyrimidines, Apoptosis, Phosphatidylinositol 3-Kinases, Cell Proliferation, Aurora Kinase A

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer. https://app.cochat.ai/papers/10.1038/s41589-018-0081-9
The paper
Donnella, H. J., Webber, J. T., Levin, R. S., Camarda, R., Momcilovic, O., Bayani, N., Shah, K. N., Korkola, J. E., Shokat, K. M., Goga, A., Gordan, J. D., & Bandyopadhyay, S. (2018). Kinome rewiring reveals AURKA limits PI3K-pathway inhibitor efficacy in breast cancer. Nature Chemical Biology. https://doi.org/10.1038/s41589-018-0081-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.